Premium Company Profile Savient Pharmaceuticals

Savient is a specialty biopharmaceutical company developing, manufacturing and marketing pharmaceutical products in both niche and broader markets. During 2006, Savient realigned its strategic focus and resources towards the clinical development and commercialization of Puricase, streamlined its product portfolio, and enhanced the company's management team.

Report Highlights
Product sales have been the major source of revenues of Savient during the period 2002-2006. Savient's total revenues decreased at a CAGR of 18% during 2002-2006, from $103 million to $48 million. Historically, Oxandrin sales have been the major contributor to the revenues of the company The company's biggest contributor to sales growth out to 2010 will be product sales from Puricase which is expected to be launched in late 2009. Oxandrin sales are expected to decrease as a result of introduction of generics Savient's strategic plan is to transform the company into a specialty biopharmaceutical business and advance the development of Puricase.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 7
Locations and Subsidiaries 9
Company Financials 10
Stock Market Performance 10
P&L 11
Balance Sheet 14
Cash Flow 14
Business Segment Performance 15
Product and services 16
Product & Service Descriptions 16
Historical Product Sales 18
AC Forecast Product Sales 20
Competitors and Strategic Business Relationships 21
Top Competitors 21
Key Suppliers 21
Key Clients 21
Strategy 22
Company View 22
Strategy 24
SWOT Analysis 25
Overview 25
Strengths 26
Weaknesses 27
Opportunities 28
Threats 29
Value Chain Analysis 31
Overview 31
Product Development 31
Scorecard 32
Overview 32
Scorecard Analysis 33
Key Employees 34
List of Key Employees 34
Key Employee Biographies 35
Financial and Operational Overview 40
Financial and Operational Overview 40
Key Industry Specific Ratios 42
APPENDIX 43
Ask the analyst 43
Datamonitor consulting 43
Disclaimer 43
[Inhaltsverzeichnis ausblenden]

Table 1: Savient - Key Facts 6
Table 2: Savient - Other Locations and Subsidiaries 9
Table 3: Savient - Year-End Share Price and Market Capitalization, 2002-2006 ($) 10
Table 4: Savient - Key Events Impacting Share Price Performance 10
Table 5: Savient - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 11
Table 6: Savient - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 13
Table 7: Savient - Balance Sheet, 2002-2006 ($ Mn) 14
Table 8: Savient - Cash Flow, 2002-2006 ($ Mn) 14
Table 9: Savient - Revenue Breakdown, 2002-2006 ($ Mn) 15
Table 10: Savient - Marketed Products 16
Table 11: Savient - In-house Pipeline Products 17
Table 12: Savient - Historical Product Sales, 2002-2006 ($ Mn) 18
Table 13: Savient - Forecast Sales, 2006-2010 ($ Mn) 20
Table 14: Savient - Key Suppliers 21
Table 15: Savient - Key Clients 21
Table 16: Savient - SWOT Analysis 25
Table 17: Savient – Value Chain Analysis 31
Table 18: Savient - Scorecard 32
Table 19: Savient - Key Employees 34
Table 20: Savient – Financial and Operational Overview 40
Table 21: Savient - Key Industry Specific Ratios 42


Figure 1: Savient - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Figure 2: Savient - Key Strategic Revenues, 2002-2006 ($ Mn) 19
[Tabellenverzeichnis ausblenden]